Safety/Efficacy of MEDI-551 in Combination with Immunomodulating Therapies in Subjects with Aggressive B-cell Lymphomas

Study identifier:D2852C00004

ClinicalTrials.gov identifier:NCT02271945

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination with Immunomodulating Therapy in Subjects with Relapsed or Refractory Aggressive B-cell Lymphomas

Medical condition

Relapsed/Refractory Aggressive B-cell Lymphomas

Phase

Phase 1/2

Healthy volunteers

No

Study drug

MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg

Sex

All

Actual Enrollment

10

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 01 Dec 2014
Primary Completion Date: 24 May 2016
Study Completion Date: 24 May 2016

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2018 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria